Kyprolis approved for multiple myeloma

(HealthDay) -- Kyprolis (carfilzomib) has been approved by the U.S. Food and Drug Administration to treat certain people with multiple myeloma who have already been given at least two prior therapies.

is a form of cancer that arises from blood plasma, usually starting in the bone marrow, the agency said in a news release. More than 21,000 people in the United States are expected to be diagnosed with the disease this year, and about 10,700 will die from it, the estimates.

Kyprolis has been approved for people treated previously with the anti-cancer drug bortezomib, and an immunomodulatory therapy such as thalidomide.

The most common side effects observed during clinical testing of Kyprolis included fatigue, low blood cell counts, low platelet counts, diarrhea and fever. More serious but less common adverse reactions included heart failure and shortness of breath, the FDA said.

Kyprolis is marketed by San Francisco-based Onyx Pharmaceuticals.

More information: Medline Plus has more about multiple myeloma.

add to favorites email to friend print save as pdf

Related Stories

FDA panel unanimously backs Onyx cancer drug

Jun 21, 2012

(AP) — A federal panel of cancer specialists on Wednesday unanimously recommended approval of an experimental drug from Onyx Pharmaceuticals Inc. for patients with advanced blood cancer.

US focuses on toxic side effects with Onyx drug

Jun 18, 2012

(AP) — The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday.

Perjeta approved for advanced breast cancer

Jun 11, 2012

(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

Nov 27, 2014

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.